Dermatitis Herpetiformis

This PatientPlus article is written for healthcare professionals so the language may be more technical than the condition leaflets. You may find the abbreviations list helpful.

Dermatitis herpetiformis (DH) is an autoimmune blistering skin disease associated with coeliac disease (gluten enteropathy).1 DH may be considered as a cutaneous manifestation of coeliac disease.2

Aetiology1

All forms of coeliac disease involve intolerance to the gliadin fraction of gluten found in wheat; there are IgA antibodies. The precise mechanism is unknown.

Epidemiology

  • For coeliac disease, UK prevalence is around 1%.3
  • Estimates of DH incidence vary. It has been suggested that approximately 15-25% of coeliac disease patients may develop DH.4,5 Another estimate is that DH affects 1 in 10,000 people.6
  • DH can appear at any age, but most commonly presents between ages 15-40 years. It is uncommon in children.6

Presentation1

Dermatitis herpetiformis is an intensely itchy bullous rash. It characteristically affects extensor surfaces, particularly the scalp, buttocks, elbows and knees. However, lesions can occur on any area of skin.

  • The lesions are papules and blisters, up to 1cm in diameter, which are extremely itchy. They arise on normal or reddened skin. Burning, stinging, and intense pruritus can precede the appearance of new lesions.
  • The severity can vary from week to week.
  • Lesions rarely resolve without specific treatment.

There may also be symptoms of coeliac disease. To see related article on coeliac disease click here.

Investigations1

Skin biopsy is usually necessary to confirm the diagnosis. The microscopic appearance of dermatitis herpetiformis is characteristic:

  • The blister is subepidermal.
  • Inflammatory cells group in the dermal papillae.
  • Direct immunofluorescence reveals IgA immunoglobulin in dermal papillae.

Blood tests:

  • May show abnormalities due to gluten enteropathy, e.g:
  • Coeliac disease can usually be detected by autoantibody testing:
    • IgA anti-tissue transglutaminase or IgA endomysial antibodies are highly specific and sensitive for untreated coeliac disease. They are also relevant to DH patients7
    • Note that these tests can be falsely negative if the patient:
      • Is already on a gluten-free diet.
      • Has selective IgA deficiency, which is more common in coeliac disease patients than in the general population.8 Therefore it may be advisable to measure serum IgA levels to identify cases of IgA deficiency;9 or to test for IgG endomysial antibodies.10
      • A small proportion of patients with coeliac disease are tissue transglutaminase antibody negative (0.4% in one series)11 and some are endomysial antibody negative. Detection rates may be improved by combining both tests.12

Other possible investigations:

  • Histocompatibility antigen typing: HLA-DR3 and DQw2 are present in most patients with coeliac disease.
  • Small bowel biopsy (may appear normal if on a gluten-free diet, or due to skip lesions in the bowel).

Differential diagnosis4

  • Erythema multiforme
  • Herpes gestationis
  • Linear IgA bullous dermatosis13
  • Eczema
  • Neurotic excoriations
  • Papular urticaria
  • Scabies
  • Transient acantholytic dermatosis

Management

A strict gluten-free diet is important in order to:1

  • Reduce the medication needed to control skin symptoms. It may be possible to discontinue dapsone when on a gluten-free diet for sufficient time.14
  • Reduce the associated enteropathy, improve nutrition and bone density.
  • Possibly, to reduce the risk of developing other autoimmune conditions and intestinal lymphoma.

Drug treatment:1,4

  • Dapsone is first choice, and reduces the itch within a day or two. Cautions and blood monitoring requirements should be noted.
  • For those intolerant or allergic to dapsone, the following may be used:
    • Sulfapyridine
    • Ultrapotent topical steroids
    • Systemic steroids
  • Avoid drugs which exacerbate DH. These may include NSAIDs (though ibuprofen seems safe) and iodides.

Complications and associated conditions1,12

Virtually all DH patients have coeliac disease, although it may be unnoticed.14 Many have thyroid disease (about 30%).

Complications may arise from problems associated with coeliac disease. These include:

Some of these problems may be improved by a gluten-free diet.

Prognosis14

  • Untreated, DH follows a prolonged course over years, with relapses and remissions. It may eventually resolve spontaneously.
  • The prognosis is good, as DH responds well to diet and medication:
    • About 80% of patients with dermatitis herpetiformis have good results from a gluten-free diet
    • It may take a year or more of this diet before medication for DH can be reduced6
    • Some patients are able to stop dapsone completely with diet treatment


Document references

  1. DermNet NZ. Dermatitis herpetiformis. New Zealand Dermatological Society Incorporated, updated December 2008. Contains pictures.
  2. Humbert P, Pelletier F, Dreno B, et al; Gluten intolerance and skin diseases. Eur J Dermatol. 2006 Jan-Feb;16(1):4-11. [abstract]
  3. West J, Logan RF, Hill PG, et al; Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut. 2003 Jul;52(7):960-5. [abstract]
  4. Miller JL et al. Dermatitis herpetiformis. emedicine, updated May 2007.
  5. Hawkes ND, Swift GL, Smith PM, et al; Incidence and presentation of coeliac disease in South Glamorgan. Eur J Gastroenterol Hepatol. 2000 Mar;12(3):345-9. [abstract]
  6. Coeliac UK, Charity for coeliac disease and dermatitis herpetiformis.
  7. Kumar V, Zane H, Kaul N; Serologic markers of gluten-sensitive enteropathy in bullous diseases. Arch Dermatol. 1992 Nov;128(11):1474-8. [abstract]
  8. Mein SM, Ladabaum U; Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2004 Jun 1;19(11):1199-210. [abstract]
  9. Hopper AD, Hadjivassiliou M, Butt S, et al; Adult coeliac disease. BMJ. 2007 Sep 15;335(7619):558-62.
  10. Korponay-Szabo IR, Szabados K, Pusztai J, et al; Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ. 2007 Dec 15;335(7632):1244-7. Epub 2007 Dec 6. [abstract]
  11. Hopper AD, Cross SS, Hurlstone DP, et al; Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. BMJ. 2007 Apr 7;334(7596):729. Epub 2007 Mar 23. [abstract]
  12. Green PH, Jabri B; Coeliac disease. Lancet. 2003 Aug 2;362(9381):383-91. [abstract]
  13. Van L, Browning JC, Krishnan RS, et al; Dermatitis herpetiformis: potential for confusion with linear IgA bullous dermatosis on direct immunofluorescence. Dermatol Online J. 2008 Jan 15;14(1):21.
  14. British Association of Dermatologists. Dermatitis herpetiformis patient information leaflet. August 2004.
  15. Askling J, Linet M, Gridley G, et al; Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002 Nov;123(5):1428-35. [abstract]

Internet and further reading

Acknowledgements

EMIS is grateful to Dr N Hartree for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2009.
Document ID: 2040
Document Version: 22
Document Reference: bgp1007
Last Updated: 7 May 2009
Provide feedback